Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China’s Green Channel Significantly Shortened Filing Time For Start-up Hua Medicine

This article was originally published in PharmAsia News

Executive Summary

Start-up Hua Medicine says IND filing time using China’s green channel shortened the review process at the provincial level.

You may also be interested in...

Meet China’s New Innovators: Hua Medicine Looks To Take Flight With U.S. Venture Backing (Part 1)

When multinational pharmaceutical companies began to establish R&D facilities in China a decade ago, they counted on Chinese returnees, or "sea turtles," to head the new centers and help them get the lay of the land. Now, MNCs may soon be partnering - or competing - with these same sea turtles who have switched gears to become China's newest entrepreneurs

Roche China R&D Center Chief Scientific Officer Li Chen On Being a Pioneer in China: An Interview With PharmAsia News (Part 2 of 2)

Swiss-headquartered Roche was the first multinational pharmaceutical outfit to establish a research and development center in China, and the company recently set up one of its PharmaPartnering groups in Shanghai. Roche's China CSO Li Chen sat down with PharmAsia News to talk about how the company is approaching R&D in the region and evolving in tandem with the pharma landscape in China. Chen is also a member of the networking organization BayHelix, which links Chinese life sciences executives.

CROs at risk from China's new inventor regulation?

China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts